FIG. 1

```
  1  CTTTCAGTCAGCATGATAGAAACATACAGCCAACCTTCCCCCAGATCCGTGGCAACTGGACTTCCAGCG   69
  1                      MetIleGluThrTyrSerGlnProSerProArgSerValAlaThrGlyLeuProAla   19

 70  AGCATGAAGATTTTTATGTATTTACTTACTGTTTTCCTTATCACCCAAATGATTGGATCTGTGCTTTTT  138
 20  SerMetLysIlePheMetTyrLeuLeuThrValPheLeuIleThrGlnMetIleGlySerValLeuPhe   42

139  GCTGTGTATCTTCATAGAAGATTGGATAAGGTCGAAGAGGAAGTAAACCTTCATGAAGATTTTGTATTC  207
 43  AlaValTyrLeuHisArgArgLeuAspLysValGluGluGluValAsnLeuHisGluAspPheValPhe   65

208  ATAAAAAAGCTAAAGAGATGCAACAAAGGAGAAGGATCTTTATCCTTGCTGAACTGTGAGGAGATGAGA  276
 66  IleLysLysLeuLysArgCysAsnLysGlyGluGlySerLeuSerLeuLeuAsnCysGluGluMetArg   88

277  AGGCAATTTGAAGACCTTGTCAAGGATATAACGTTAAACAAAGAAGAGAAAAAAGAAAACAGCTTTGAA  345
 89  ArgGlnPheGluAspLeuValLysAspIleThrLeuAsnLysGluGluLysLysGluAsnSerPheGlu  111

346  ATGCAAAGAGGTGATGAGGATCCTCAAATTGCAGCACACGTTGTAAGCGAAGCCAACAGTAATGCAGCA  414
112  MetGlnArgGlyAspGluAspProGlnIleAlaAlaHisValValSerGluAlaAsnSerAsnAlaAla  134

415  TCCGTTCTACAGTGGGCCAAGAAAGGATATTATACCATGAAAAGCAACTTGGTAATGCTTGAAAATGGG  483
135  SerValLeuGlnTrpAlaLysLysGlyTyrTyrThrMetLysSerAsnLeuValMetLeuGluAsnGly  157

484  AAACAGCTGACGGTTAAAAGAGAAGGACTCTATTATGTCTACACTCAAGTCACCTTCTGCTCTAATCGG  552
158  LysGlnLeuThrValLysArgGluGlyLeuTyrTyrValTyrThrGlnValThrPheCysSerAsnArg  180

553  GAGCCTTCGAGTCAACGCCCATTCATCGTCGGCCTCTGGCTGAAGCCCAGCAGTGGATCTGAGAGAATC  621
181  GluProSerSerGlnArgProPheIleValGlyLeuTrpLeuLysProSerSerGlySerGluArgIle  203

622  TTACTCAAGGCGGCAAATACCCACAGTTCCTCCCAGCTTTGCGAGCAGCAGTCTGTTCACTTGGGCGGA  690
204  LeuLeuLysAlaAlaAsnThrHisSerSerSerGlnLeuCysGluGlnGlnSerValHisLeuGlyGly  226
```

FIG. 1, continued

```
691   GTGTTTGAATTACAAGCTGGTGCTTCTGTGTTTGTCAACGTGACTGAAGCAAGCCAAGTGATCCACAGA   759
227   ValPheGluLeuGlnAlaGlyAlaSerValPheValAsnValThrGluAlaSerGlnValIleHisArg   249

760   GTTGGCTTCTCATCTTTTGGCTTACTCAAACTCTGAACAGTGCGCTGCCCTAGGCTGCAGCAGGGCTGA   828
250   ValGlyPheSerSerPheGlyLeuLeuLysLeu                                        260

829   TGCTGGCAGTCTCCCCTATACACCAAGTCAGTTAGGCCCTCCCCTGTGTTGAACTGCCTATTTATAACC   897

898   CTAGGATCCTCCTCATGGAGAACTATTTATTATGTACCCCCAAGGCACATAGAGCTGGAATAAGAGAAT   966

967   TACAGGGCAGGCAAAAATCCCAAGGGACCCTGCTCCCTAAGAACTTACAATCTGAAACAGCAACCCCAC   1035

1036  TGATTCAGACAACCAGAAAAGACAAAGCCATAATACACAGATGACAGAGCTCTGATGAAACAACAGATA   1104

1105  ACTAATGAGCACAGTTTTGTTGTTTTATGGGTGTGTCGTTCAATGGACAGTGTACTTGACTTACCAGGG   1173

1174  AAGATGCAGAAGGGCAACTGTGAGCCTCAGCTCACAATCTGTTATGGTTGACCTGGGCTCCCTGCGGCC   1242

1243  CTAGTAGG                                                                 1250
```

FIG. 2

```
  1  TGCCACCTTCTCTGCCAGAAGATACCATTTCAACTTTAACACAGCATGATCGAAACATACAACCAAACT   69
  1                                                MetIleGluThrTyrAsnGlnThr    8

 70  TCTCCCCGATCTGCGGCCACTGGACTGCCCATCAGCATGAAAATTTTTATGTATTTACTTACTGTTTTT  138
  9  SerProArgSerAlaAlaThrGlyLeuProIleSerMetLysIlePheMetTyrLeuLeuThrValPhe   31

139  CTTATCACCCAGATGATTGGGTCAGCACTTTTTGCTGTGTATCTTCATAGAAGGTTGGACAAGATAGAA  207
 32  LeuIleThrGlnMetIleGlySerAlaLeuPheAlaValTyrLeuHisArgArgLeuAspLysIleGlu   54

208  GATGAAAGGAATCTTCATGAAGATTTTGTATTCATGAAAACGATACAGAGATGCAACACAGGAGAAAGA  276
 55  AspGluArgAsnLeuHisGluAspPheValPheMetLysThrIleGlnArgCysAsnThrGlyGluArg   77

277  TCCTTATCCTTACTGAACTGTGAGGAGATTAAAAGCCAGTTTGAAGGCTTTGTGAAGGATATAATGTTA  345
 78  SerLeuSerLeuLeuAsnCysGluGluIleLysSerGlnPheGluGlyPheValLysAspIleMetLeu  100

346  AACAAAGAGGAGACGAAGAAAGAAAACAGCTTTGAAATGCAAAAAGGTGATCAGAATCCTCAAATTGCG  414
101  AsnLysGluGluThrLysLysGluAsnSerPheGluMetGlnLysGlyAspGlnAsnProGlnIleAla  123

415  GCACATGTCATAAGTGAGGCCAGCAGTAAAACAACATCTGTGTTACAGTGGGCTGAAAAAGGATACTAC  483
124  AlaHisValIleSerGluAlaSerSerLysThrThrSerValLeuGlnTrpAlaGluLysGlyTyrTyr  146

484  ACCATGAGCAACAACTTGGTAACCCTGGAAAATGGAAACAGCTGACCGTTAAAAGACAAGGACTCTAT  552
147  ThrMetSerAsnAsnLeuValThrLeuGluAsnGlyLysGlnLeuThrValLysArgGlnGlyLeuTyr  169

553  TATATCTATGCCCAAGTCACCTTCTGTTCCAATCGGGAAGCTTCGAGTCAAGCTCCATTTATAGCCAGC  621
170  TyrIleTyrAlaGlnValThrPheCysSerAsnArgGluAlaSerSerGlnAlaProPheIleAlaSer  192

622  CTCTGCCTAAAGTCCCCCGGTAGATTCGAGAGAATCTTACTCAGAGCTGCAAATACCCACAGTTCCGCC  690
193  LeuCysLeuLysSerProGlyArgPheGluArgIleLeuLeuArgAlaAlaAsnThrHisSerSerAla  215
```

FIG. 2, continued

```
691  AAACCTTGCGGGCAACAATCCATTCACTTGGGAGGAGTATTTGAATTGCAACCAGGTGCTTCGGTGTTT  759
216  LysProCysGlyGlnGlnSerIleHisLeuGlyGlyValPheGluLeuGlnProGlyAlaSerValPhe  238

760  GTCAATGTGACTGATCCAAGCCAAGTGAGCCATGGCACTGGCTTCACGTCCTTTGGCTTACTCAAACTC  828
239  ValAsnValThrAspProSerGlnValSerHisGlyThrGlyPheThrSerPheGlyLeuLeuLysLeu  261

829  TGAACAGTGTCACCTTGCAGGCTGTGGTGGAGCTGACGCTGGGAGTCTTCATAATACAGCACAGCGGTT  897

898  AAGCCCACCCCCTGTTAACTGCCTATTTATAACCCTAGGATCCTCCTTATGGAGAACTATTTAT      961
```

FIG. 3

```
1   MIETYNQTSPRSAATGLPISMKIFMYLLTVFLITQMIGSALFAVYLHRRL  50
5   MIETYSQPSPRSVATGLPASMKIFMYLLTVFLITQMIGSVLFAVYLHRRL  54

51  DKIEDERNLHEDFVFMKTIQRCNTGERSLSLLNCEEIKSQFEGFVKDIML  100
55  DKVEEEVNLHEDFVFIKKLKRCNKGEGSLSLLNCEEMRRQFEDLVKDITL  104

101 NKEETKKENSFEMQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSN  150
105 NKEE.KKENSFEMQRGDEDPQIAAHVVSEANSNAASVLQWAKKGYYTMKS  153

151 NLVTLENGKQLTVKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGR  200
154 NLVMLENGKQLTVKREGLYYVYTQVTFCSNREPSSQRPFIVGLWLKPSSG  203

201 FERILLRAANTHSSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHG  250
204 SERILLKAANTHSSSQLCEQQSVHLGGVFELQAGASVFVNVTEASQVIHR  253

251 TGFTSFGLLKL  261
254 VGFSSFGLLKL  264
```

FIG. 4A


10E5 E- + CV1's
4000
3000
2000
1000
0
CPM
10^2
10^3
10^4
10^5
Number of CV1's
HAV EO
CD40L

FIG. 4B


10E5 E- + IL-4 + CV1's
6000
5000
4000
3000
2000
1000
0
CPM
10^2
10^3
10^4
10^5
Number of CV1's
HAV EO
CD40L

FIG. 5

PB E + IL-4 + CV1 d7 Proliferation



FIG. 6

S.CD23 in Day 6 Cultures S/N:
10E5 E-/Well, IMDM + IL-4



FIG. 7

S.CD23 in Day 6 Cultures S/N:
10E5 E-/Well, IMDM + IL-4



FIG. 8

Induction of B Cell Proliferation by CD40 Ligand Expressing CV-1 Cells (fixed)



FIG. 9

Induction of Anti-SRBC PFC by EL4 40.9 and 7A1 Th1 Cells (Fixed)



FIG. 10

Induction of B Cell Proliferation by CD40 Ligand Expressing CV-1 Cells



FIG. 11

Induction of Anti-SRBC PFC by CD40 Ligand Expressing CV-1 Cells (fixed)



3194-11

FIG. 12

Induction of Murine B Cell Proliferation by CD40 Ligand Expressing CV-1 Cels (fixed)



INDUCTION OF ANTIGEN SPECIFIC PFC BY CD40 LIGAND EXPRESSING CV-1 CELLS (FIXED)



FIG. 13A



FIG. 13B

FIG. 14A

Day 7 Proliferation of T-depleted PBM



FIG. 14B

Day 10 IgE Secretion from T-depleted PBM



FIG. 15A



FIG. 15B



FIG. 15C



FIG. 15D



BINDING OF CD40.Fc AND ANTI-CD40L ANTIBODY M90
TO ACTIVATED PERIPHERAL BLOOD T CELLS

FIG. 16A



FIG. 16B



FIG. 16C



FIG. 16D



INHIBITON OF CD40.Fc BINDING TO ACTIVATED PERIPHERAL BLOOD T CELLS BY ANTI-CD40L ANTIBODIES M90 AND M91

Inhibition of anti-IgM + soluble CD40L-induced B-cell proliferation by anti-hCD40L mAb



FIG. 17

Binding of human and Murine CD40 LT and CD40 L Fc Dimer to CD40Fc by Biosensor Assay



FIG. 18

FIG. 19A



FIG. 19B



BINDING OF CD40 LIGANDS TO CD40Fc USING EQUILIBRIUM BINDING VALUES ESTIMATED FROM A KINETIC ANALYSIS OF THE ASSOCIATION PHASE